Regeneron: halts Covid-19 trial
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals announce the halt of the Kevzara (sarilumab) phase III trial in patients with Covid-19 infection requiring mechanical ventilation, reporting adverse events.
Both the pharma groups also explain that this test did not meet its primary and secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
However, they state that a separate trial, piloted by Sanofi, using a different dosing regimen, is ongoing outside the US in hospitalised patients for a severe and critical form of Covid-19.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Both the pharma groups also explain that this test did not meet its primary and secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
However, they state that a separate trial, piloted by Sanofi, using a different dosing regimen, is ongoing outside the US in hospitalised patients for a severe and critical form of Covid-19.
Copyright (c) 2020 CercleFinance.com. All rights reserved.